ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor // Chi-Med
News Archive
Previous Article   |   Next Article
Presentations | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor